FDA Grants AP Status for Risperidone ANDA077494 Submission
The FDA's grant of Abbreviated New Drug Application (ANDA) approval status for Risperidone indicates a significant shift in the competitive landscape. This could lead to increased market competition and pressure on pricing strategies for current branded products.
Asset
Risperidone
Indication
Psychiatry / Antipsychotic
Status
Approved
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The FDA's grant of Abbreviated New Drug Application (ANDA) approval status for Risperidone indicates a significant shift in the competitive landscape. This could lead to increased market competition and pressure on pricing strategies for current branded products.
Why it matters
The FDA's grant of Abbreviated New Drug Application (ANDA) approval status for Risperidone indicates a significant shift in the competitive landscape. This could lead to increased market competition and pressure on pricing strategies for current branded products.
What changed
Regulatory Approval
Analysis
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Risperidone under application number ANDA077494.
The FDA's grant of Abbreviated New Drug Application (ANDA) approval status for Risperidone indicates a significant shift in the competitive landscape. This could lead to increased market competition and pressure on pricing strategies for current branded products.
Monitor the timeline for final approval and market entry of the generic Risperidone by PH HEALTH.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.